Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204

Rhea-AI Summary

Marvel Biosciences (OTCQB: MBCOF) has secured a significant patent in China for its lead therapeutic candidate MB-204, a novel fluorinated derivative of Istradefylline. The patent (ZL202180020893.4) covers the compound's composition of matter, which is designed to target autism spectrum disorder and related conditions.

MB-204 has demonstrated enhanced potency, longer duration, and improved tolerability in preclinical studies, showing efficacy in models of autism, Rett syndrome, and depression. The company is preparing to advance the drug candidate into Phase 1 clinical trials, addressing a significant market need with approximately 1 in 36 children diagnosed with autism.

Positive

• Patent granted in China strengthens global intellectual property position
• MB-204 showed strong preclinical efficacy across multiple disease models
• Drug candidate ready to enter Phase 1 clinical trials
• Enhanced drug properties including superior potency and improved tolerability

Negative

• None.

News Market Reaction

+3.98%

1 alert

+3.98% News Effect

On the day this news was published, MBCOF gained 3.98%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Calgary, Alberta--(Newsfile Corp. - August 18, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively "Marvel" or the "Company"), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced that the China National Intellectual Property Administration (CNIPA) has granted patent number ZL202180020893.4, titled "Purine Compounds for Treating Disorders". The patent covers the composition of matter for Marvel's lead asset, MB-204.

MB-204 is a novel, fluorinated derivative of the adenosine A2A receptor antagonist Istradefylline, engineered for superior potency, longer duration, and improved tolerability. It has demonstrated strong preclinical efficacy across multiple models of autism, Rett syndrome, and depression, and is ready to enter Phase 1 clinical trials.

"This allowance further strengthens our global IP position in a key market," said J. Roderick Matheson, CEO of Marvel Biosciences. "Securing these rights is an important step, and we look forward to achieving similar outcomes in other key jurisdictions". With approximately one in 36 children diagnosed with autism, there is a clear need for innovation. "We remain committed to advancing MB-204 through the clinic to address these significant unmet medical needs."

About Marvel Biosciences Corp.
Marvel Biosciences Corp., through its wholly owned subsidiary Marvel Biotechnology Inc., is a Calgary-based biotechnology company developing new treatments for neurological diseases and neurodevelopmental disorders. Our lead drug candidate, MB-204, is a novel fluorinated derivative version of Istradefylline, an approved Parkinson's drug and the only adenosine A2A receptor blocker currently on the market.

Research shows that blocking the A2A receptor may help treat conditions such as autism, depression, and Alzheimer's disease. Marvel is also exploring MB-204's potential in rare disorders like Rett syndrome and Fragile X syndrome, aiming to bring new options to patients with few effective treatments.

Contact Information:

Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer 
Tel: 403 770 2469

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary,(collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/262961

FAQ

What patent did Marvel Biosciences (MBCOF) receive in China?

Marvel Biosciences received Chinese patent number ZL202180020893.4, titled 'Purine Compounds for Treating Disorders', covering the composition of matter for their lead asset MB-204.

What conditions is Marvel Biosciences' MB-204 designed to treat?

MB-204 is being developed to treat autism spectrum disorder, Rett syndrome, depression, and related conditions, with preclinical studies showing efficacy across multiple disease models.

What are the key advantages of Marvel Biosciences' MB-204 drug candidate?

MB-204 is engineered for superior potency, longer duration, and improved tolerability compared to Istradefylline, its parent compound.

What is the current development stage of Marvel Biosciences' MB-204?

MB-204 has completed preclinical studies and is ready to enter Phase 1 clinical trials.

What is the market potential for Marvel Biosciences' autism treatment?

There is a significant market need, with approximately 1 in 36 children being diagnosed with autism, representing a substantial opportunity for innovative treatments.